Effect of GM1 ganglioside treatment on the recovery of dopaminergic nigro-striatal neurons after different types of lesion

The effect of GM1 ganglioside treatment on the recovery of biochemical and behavioral parameters which define the activity of nigro-striatal dopaminergic systems has been investigated in rats after different types of lesion. GM1 favours the recovery of tyrosine-hydroxylase activity, of the number and affinity of 3H-N-n-propyl-norapomorphine binding sites in the striatum of the lesioned side and reduces the apomorphine-induced rotational behavior after mechanical (i.e. unilateral hemitransection) but not after chemical (i.e. 6-OHDA injected in the substantia nigra) lesion. The source of regrowing dopaminergic nerve terminals in the striatum after hemitransection is mainly a response of intact remaining axons of the ipsilateral side. Moreover the contralateral nigro-striatal systems seems to play, through intrathalamic connections, an important role in regulating the GM1-induced increase of the tyrosine-hydroxylase activity.

Autoradiographic localization of dopamine receptors in the spinal cord of the rat using [3H]-N-propylnorapomorphine

Dopamine receptors were localized autoradiographically in the rat spinal cord after in vitro labelling using 3H-N-propylnorapomorphine (NPA). The highest densities of 3H-NPA binding sites were found in the substantia gelatinosa and in a zone of the grey matter immediately ventral to the dorsal corticospinal tract. Other areas of the grey matter presented only moderate or low receptor densities while no 3H-NPA binding sites could be found in the white matter. The localization of 3H-NPA binding sites is compatible with a role for spinal cord dopamine in the processing of sensory information.

Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]

The (+)-enantiomer of 1,2,3,4a,5,6-hexahydro-9-hydroxy-4-n-propyl-4H-naphth[1,2-b][ 1,4]-oxazine [(+)-PHNO] is demonstrated to be a potent and direct dopamine (DA) agonist in several in vivo and in vitro test procedures. In vitro (+)-PHNO inhibited binding of [3H]apomorphine (IC50 = 23 nM) or [3H]spiperone (IC50 = 55 nM) to rat striatal membranes. Because (+)-PHNO failed to stimulate adenylate cyclase in carp retina, it was classified as a D-2 agonist. ED50 values (shown in parentheses) derived in DA receptor-related in vivo tests were as follows: in mice, (+)-PHNO produced hypothermia (13 micrograms/kg i.p.) and postural asymmetry in the unilaterally caudectomized animal (4 micrograms/kg i.p.). In the rat, (+)-PHNO produced stereotypy (10 micrograms/kg i.p.) and contralateral turning in 6-hydroxydopamine-lesioned animals (5 micrograms/kg i.p.) that lasted 1 to 3 hr. Whereas both of the latter effects were blocked by haloperidol, prior treatment with depletors of endogenous catecholamines, reserpine or alpha-methylparatyrosine failed to reduce (+)-PHNO-induced stereotypy. The naphthoxazine also produced emesis in beagles (0.05 micrograms/kg i.v.) that was blocked by L-646,462, a peripherally selective DA receptor antagonist. (+)-PHNO was well absorbed when given p.o., producing contralateral turning (10 micrograms/kg) with a ratio of p.o. to i.p. ED50 values of 2. This ratio was much lower than those derived for n-propylnorapomorphine (60) and apomorphine (54). At the DA autoreceptor, (+)-PHNO inhibited the accumulation of dOPA in the gamma-butyrolactone-treated rat (11 micrograms/kg i.p.).(ABSTRACT TRUNCATED AT 250 WORDS)

Binding of [3H]apomorphine to an aporphine binding site as well as to dopamine sites in tissue from bovine caudate nucleus

Binding of the tritiated dopamine (DA) agonists, apomorphine (APO) and a dihydroxyaminotetralin (ADTN) to a membrane preparation from the caudate nucleus of calf brain was compared. Binding of [3H]dihydroxyaminotetralin at small (nM) concentrations followed simple, monophasic inhibition (over 80% at less than 500 nM) by concentrations of apomorphine between 50 pM and 1 mM. Inhibition of the binding of [3H]apomorphine by dihydroxyaminotetralin was more complex, and included in component with a low (microM) affinity for dihydroxyaminotetralin accounting for approx. 20% of total binding. The kinetics of binding of the ligands to high-affinity sites were virtually identical (apparent Kd = 0.81 nM; Bmax = 211 fmol/mg protein) and could not be distinguished by curve-fitting techniques adapted to analysis by microcomputer. In contrast, the binding of [3H]apomorphine with a "blank" defined by excess (10 microM) dihydroxyaminotetralin could be resolved into the same high-affinity component and a lower-affinity site (Kd = 124 nM; Bmax = 5740 fmol/mg). The pharmacology of the lower-affinity binding of [3H]apomorphine was evaluated by coincubating with 0.5 microM dihydroxyaminotetralin to "mask" high-affinity sites, and was compared to high-affinity binding of [3H]apomorphine and [3H]dihydroxyaminotetralin. The high-affinity binding was stereoselective for DA receptor agonists and antagonists. The pharmacology of the lower-affinity site resembled no known DA receptor type and showed highest affinities for aporphines but was not stereoselective and reacted weakly and nonspecifically with dihydroxyaminotetralin, DA, other catecholamines and neuroleptics. Thus, [3H]apomorphine, under certain conditions, may detect an aporphine binding site of uncertain pharmacological significance, as well as high-affinity DA agonist (D-3) sites.

In vivo binding of N-n-propylnorapomorphine in the rat striatum: quantification after lesions produced by kainate, 6-hydroxydopamine and decortication

The neuronal localization of in vivo N-n-propylnorapomorphine (NPA) binding in the rat striatum was studied using 3 types of lesions. Striatal dopamine (DA) receptor densities (Bmax) were estimated from the relationships between total striatal and cerebellar NPA accumulation. A Bmax of 26.9 +/- 1.6 fmol X mg-1 wet weight tissue was found in the striata of non-lesioned (unoperated) rats. Similar values were obtained for striata with 6-hydroxydopamine-lesioned dopaminergic fibres. Kainate (KA)-lesioned striata contained 4.6 +/- 0.5 fmol X mg-1 saturable NPA binding sites. After unilateral decortication the receptor densities were in both striata resulting in ipsi- and contralateral Bmax values of 23 and 36 fmol X mg-1 respectively. With a tracer dose of [3H]NPA less radioactivity accumulated in the KA-lesioned striatum, while after unilateral destruction of the dopaminergic pathway more radioactivity was found in the ipsilateral striatum and no bilateral differences in striatal radioactivity concentration were found after unilateral cortical ablation. These observations show that all in vivo saturable striatal NPA binding sites are situated on striatal neurons and cortico-striatal afferents and that the effects of lesions on striatal DA receptor densities cannot be predicted from bilateral differences in the accumulation of tracer doses of [3H]NPA.

Dopamine receptor binding sites in the rat superior colliculus

Following intravenous administration of [3H]spiperone or [3H]N,n-propylnorapomorphine (NPA) to rats, radioactivity derived from the ligands accumulated in the striatum and superior colliculus when compared with cerebellar levels. The accumulation of [3H]spiperone in both areas was prevented by intraperitoneal administration of (+)-butaclamol, haloperidol and sulpiride but not by (-)-butaclamol, cinanserin, propranolol or prazosin. The accumulation of [3H]NPA was prevented by administration of (+)-butaclamol, haloperidol and apomorphine but not by (-)-butaclamol. In in-vitro experiments, membrane preparations from the superior colliculus showed a small number of specific binding sites for both [3H]spiperone and [3H]NPA. The dissociation constant (KD) for [3H]NPA was not different from that for striatal preparations but that for [3H]spiperone was 10-fold higher. We conclude that dopamine receptors may be present within the superior colliculus.

Effect of age on behavioral responses and tissue levels of apomorphine in the rat

Rats of several ages between 2 and 24 months were tested for stereotyped behavioral responses to R(-)apomorphine-HCl (APO), a potent and selective dopamine agonist. Between 2 and 24 months, the ED50 for apomorphine decreased 2.5-fold (0.14-0.06 mg/kg, i.p.), as assessed by a microcomputer-assisted technique. Not only were older rats more sensitive to apomorphine, but the duration of the behavioral effects increased with age and showed a greater change at doses which were greater than the ED50. When levels of apomorphine in brain were assayed by liquid chromatography and electrochemical detection, there was a progressive increase in peak levels of the agent in the tissue as well as a delay in its elimination from brain, with increasing age. Moreover, there was a highly significant correlation between increased behavioral effect and the level of apomorphine in brain with increasing age (r greater than 0.8). These results indicate that increased levels in brain or decreased elimination of apomorphine may be an important factor contributing to a marked increase in behavioral sensitivity to apomorphine with age in the rat.

Chronic dihydroergotoxine treatment affects the number of dopamine recognition sites in rat striatum

Ergot derivatives have been proposed to have ameliorative effects in various pathological conditions where dopaminergic transmission is believed to be impaired, namely Parkinson's disease, amenorrhea-galactorrhea syndrome, and in the treatment of behavioural disturbances of the elderly. To get more insight into a possible involvement of a direct action of ergot derivatives on dopamine receptors we studied the effect of acute and chronic dihydroergotoxine (DHT) treatment on 3H-Spiroperidol and 3H-N-Propylnorapomorphine (3H-NPA) binding to rat striatal membrane preparations. The results are in favor of an interaction of ergot derivatives with dopamine recognition sites both after acute and chronic treatment.

l-Glutamate reduces the affinity of [3H]N-propylnorapomorphine binding sites in striatal membranes

l-Glutamate but not methyl-D-aspartate (NMDA) or quisqualate ( Quis ) (10(-6 M) in vitro with or without preincubation increased significantly the KD value of the [3H]N-propylnorapomorphine ( [3H]NPA) binding sites by 21 and 36% respectively in striatal membranes of rat without influencing the striatal [3H]spiperone binding sites. The number of striatal [3H]NPA binding sites was not changed by l-glutamate (10(-6) and 10(-5) M) in vitro. There may thus exist interactions between striatal glutamate receptors -- not related to excitatory amino-acid receptors of the NMDA or the QUIS type -- and high affinity striatal DA receptors.

Dopaminergic binding sites in rat striatal slices and the action of guanyl nucleotides

Dopaminergic binding sites were studied in slices from rat striatum incubated in a physiological medium and using the two highly selective ligands 3H-apomorphine and 3H-domperidone. The clearly biphasic or stretched inhibition of the specific binding of these two ligands by domperidone or apomorphine, respectively allowed to define three distinct classes of binding site. It was demonstrated, by comparing the binding of the 3H-ligand added at the beginning of slice incubation or just before homogenisation of tissue and filtration, that the "specific" bindings only occurred during the incubation of slices. The inhibition constants (Ki values) of dopaminergic agents for the three classes of binding site as also the dissociation constants (Kd values) of 3H-ligands and the maximal capacity (Bmax) of the three classes of binding site were closely similar to those of binding sites previously demonstrated on rat striatal membranes, namely D-2, D-3 and D-4 sites (Sokoloff et al. 1980 a, b). Their identification on a preparation in which the cellular organisation is largely preserved rules out the possibility that these sites represent an artifact due to membrane preparation. Unexpectedly the addition of guanyl nucleotides like GTP or GppNHp to the slice preparation decreased the binding of 3H-apomorphine to the high affinity sites (particularly to the D-2 sites) while D-4 site binding was correspondingly increased. The guanyl nucleotide effect apparently took place before cell disruption and occurred at concentrations similar to those required in striatal membrane preparations. These observations, together with those indicating the presence of high affinity binding sites for dopaminergic agonists in intact striatal cells, suggest that a putative nucleotide regulatory unit of dopamine receptors, is not fully occupied by intracellular GTP but could be interacted with from the external face of the cell membrane.

Interaction of (+)- and (-)-3-PPP with the dopamine receptor in the anterior pituitary gland

The interaction of the enantiomers of the novel dopamine agonist, 3-PPP (3-hydroxyphenyl)-N-n-piperidine) with the dopamine receptor in the anterior pituitary gland was examined. Both (+)- and (-)-3-PPP were effective in suppressing the elevation in serum prolactin (PRL) concentrations in rats treated with alpha-methyl-paratyrosine, an inhibitor of dopamine synthesis. The (+)-enantiomer was slightly more potent than the (-)-enantiomer in this regard. In addition, the secretion of PRL from anterior pituitary tissue under in vitro conditions was significantly inhibited by both isomers of 3-PPP, with (+)-3-PPP being approximately 10 times more potent than (-)-3-PPP. Both (+)- and (-)-3-PPP displaced 3H-(-)-N-n-propylnorapomorphine (3H-NPA) and 3H-spiperone from bovine anterior pituitary membranes. The Hill coefficients of (+)- and (-)-3-PPP for the displacement of 3H-spiperone were 0.6 and 0.7, respectively. These results are consistent with the view that the (+)- and (-)-enantiomer exhibit dopamine agonist effects at dopamine receptor sites in the anterior pituitary gland. However, (+)-3-PPP demonstrated marked differences in affinity for 3H-NPA- and 3H-spiperone labeled-sites, whereas (-)-)3-PPP showed the same order of affinity for these two sites. In view of these results and the fact that (-)-3-PPP has also been characterized as a dopamine antagonist at postsynaptic receptor sites in the striatum, (-)-3-PPP might be best described as a partial agonist at pituitary dopamine receptors. Moreover, these data are suggestive of a similarity, at least on a pharmacological basis, between dopamine autoreceptors and dopamine receptors in the anterior pituitary gland.

Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats

Rats received therapeutically equivalent doses of either haloperidol (1.7-1.9 mg/kg/day), sulpiride (112-116 mg/kg/day) or clozapine 30-35 mg/kg/day) continuously for 4 weeks. Treatment with haloperidol, but not sulpiride or clozapine, caused inhibition of stereotyped behaviour induced by apomorphine (0.125-0.25 mg/kg SC). Following drug withdrawal for up to 7 days, haloperidol and sulpiride, but not clozapine treatment caused an exaggeration of stereotyped behaviour induced by apomorphine. Bmax values for striatal 3H-spiperone binding were elevated in animals treated for 2 and 4 weeks with haloperidol, but not with sulpiride or clozapine. Following drug withdrawal, haloperidol, but not sulpiride or clozapine, treatment caused an increase in Bmax for striatal 3H-spiperone binding. Bmax values for striatal 3H-NPA binding revealed no change during haloperidol or clozapine treatment. Sulpiride treatment for 1 week caused an increase in Bmax for 3H-NPA binding, which returned to control levels at 2 and 4 weeks. Following drug withdrawal, there was an increase in Bmax for 3H-NPA binding in rats treated with haloperidol and sulpiride, but not clozapine. On continuous treatment and following withdrawal from haloperidol, sulpiride, or clozapine the ability of dopamine to stimulate striatal adenylate cyclase activity did not differ from that in control animals. Repeated administration of sulpiride or clozapine may not induce striatal dopamine receptor supersensitivity when given in clinically relevant doses, although haloperidol does.

Studies on the mechanism of action of substituted benzamide drugs

The effects of classical neuroleptic drugs (haloperidol, chlorpromazine) and atypical neuroleptics, i.e. substituted benzamides (L-sulpiride, tiapride, FLA 731(-] on specific in vivo binding of the dopamine antagonist 3H-spiperone and the dopamine agonist 3H-n-propylnorapomorphine (3H-NPA) was examined in male rats. The atypical neuroleptics were found to be considerably more potent in displacing nigral than striatal 3H-spiperone binding while the classical neuroleptics were about equipotent in the two brain regions. The benzamides also produced considerably less displacement of 3H-spiperone in the striatum than did classical neuroleptics. Furthermore, while the classical neuroleptic drugs block the striatal 3H-spiperone and 3H-NPA binding sites to about the same degree, the substituted benzamides appear to have a higher affinity for the DA receptors labelled by 3H-NPA than those labelled by 3H-spiperone. The behavioural effects of the benzamides were found to differ from classical neuroleptic drugs particularly with regard to induction of catalepsy. Thus, the induction of cataleptic behaviour was found to correlate with displacement of 3H-spiperone in the striatum while blockade of apomorphine induced hyperactivity correlated with the displacement of spiperone in extrastriatal areas.

Subcortical limbic 3H-N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro

By means of the dopamine (DA) agonist radio ligand 3H-N-propylnorapomorphine (3H-NPA) the effects of cholecystokinin-8 (CCK-8) have been evaluated in vitro on the binding characteristics of the DA agonist sites in membrane preparations from the subcortical limbic forebrain containing mainly nucleus accumbens and tuberculum olfactorium. It was shown that CCK-8 (10(-8) M) can produce a 40% increase in the KD value of the 3H-NPA binding sites and a significant 10% increase in the Bmax values of these sites. It is therefore suggested that there exist marked receptor-receptor interactions between the CCK-8 binding sites and DA agonist binding sites in the limbic forebrain. On the basis of these findings and in view of the fact that CCK peptides are comodulators in certain types of mesolimbic DNA neurons but cannot modulate DA release in these DNA synapses, the hypothesis is introduced that the presence of DA comodulators such as CCK-8 in the DA synapses makes possible a heterostatic regulation of the synapse. Thus, by means of receptor-receptor interactions, peptide comodulators may change the set point of the main transmission line without inducing homeostatic feedback responses on synthesis and release of the main transmitter, opening up a new way to modulate chemical transmission in general.

Correspondency between different affinity states and target size of the bovine striatal D2 dopamine receptor

Target size analysis of the D2 dopamine receptor in the bovine striatum revealed the presence of two populations of this receptor, in terms of apparent molecular size. The size of large target was approximately 150 X 10(4) daltons, while that of small target was 11 X 10(4) daltons. The antagonist [3H]spiperone labeled both large and small sized D2 receptors, while agonist [3H]n-propylapomorphine (NPA) labeled only the former. In addition, the apparent molecular size of a functional unit for the GTP effect was calculated to be 150 X 10(4) daltons, such appearing to be identical to that of large target sized D2 dopamine receptors. Therefore, the large sized D2 receptor, probably an oligomeric complex consisting of D2 receptor recognition protein and guanine nucleotide regulatory protein, has a high affinity for both agonist and antagonist, while the small sized receptor, probably a monomeric or dimeric receptor recognition protein, has a high affinity for only the antagonist.

Localization of [3H]N-propylnorapomorphine binding in mouse striatum

The anatomic localization of specific striatal [3H]N-propylnorapomorphine ( [3H]PNA) binding was determined in male C57BL/6J mice. Striatal [3H]PNA binding was high affinity and sensitive to guanine nucleotides. Frontal cortical ablation did not alter striatal [3H]PNA binding, but reduced [3H]spiperone binding by 36%. Kainic acid reduced and 6-hydroxydopamine elevated [3H]PNA binding. A combined frontal cortical ablation and striatal kainic acid lesion was similar to that of kainate alone. These data are consistent with a localization of [3H]PNA binding sites on neurons intrinsic to the mouse striatum.

Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration

Inclusion of phenoxybenzamine into incubates containing rat striatal preparations equipotently displaced specific striatal [3H]spiperone and [3H]NPA binding. Pre-incubation of striatal membranes with phenoxybenzamine followed by extensive washing equipotently inhibited the subsequent specific [3H]spiperone or [3H]NPA binding. In both displacement and pre-incubation experiments phenoxybenzamine caused complete inhibition of specific [3H]spiperone binding to rat striatal membranes, but only partially inhibited specific [3H]NPA binding. Following parenteral administration to rats, phenoxybenzamine caused a marked inhibition of ex vivo specific [3H]spiperone binding in striatal tissue preparations from these animals which lasted approximately 24 hr following in vivo drug administration. In contrast, administration of phenoxybenzamine caused only a transient change in ex vivo specific [3H]NPA binding. Phenoxybenzamine causes irreversible inhibition of [3H]spiperone and [3H]NPA binding in vitro. In vivo administration of phenoxybenzamine discriminates between [3H]spiperone and [3H]NPA in ex vivo studies suggesting that these binding sites have different turnover rates.

Effect of chronic ethanol treatment on adenylate cyclase activity in rat striatum

Chronic ethanol consumption induces an increase in striatal adenylate cyclase enzymatic activity but is unable to further potentiate the dopamine stimulated production of cyclic-AMP. In striatal membranes obtained from chronic ethanol-treated rats, apomorphine exerts a more potent inhibition of [3H]spiperone binding when compared with controls, demonstrating that ethanol increases the affinity of the dopaminergic receptors associated with adenylate cyclase activity. In addition, GTP is unable to modify the agonist component of dopamine receptor in membrane exposed 'in vivo' to ethanol. Data are discussed in terms of a derangement of receptor-adenylate cyclase coupling system produced by chronic ethanol treatment.

Redox delivery system for brain-specific, sustained release of dopamine

Dopamine was transformed into a redox chemical system for delivery to the brain. The lipoidal form allowed penetration of the blood-brain barrier. Oxidative and hydrolytic processes then transformed the delivery form into a quaternary ammonium precursor of dopamine. The quaternary ammonium precursor was rapidly eliminated from the general circulation, whereas that formed in the brain was locked in, thereby providing a significant and sustained brain-specific dopaminergic activity.

Facilitation by alpha-adrenolytics of apomorphine gnawing behavior: depression of threshold apomorphine concentration in the striatum of the rat

Adrenolytics, aceperone and phenoxybenzamine, increased significantly the incidence of gnawing induced in the rat by a medium dose of apomorphine. The experiments in which the rats were killed at the onset of stereotyped gnawing to assess the threshold concentration of apomorphine in the striatum necessary to evoke this type of behavior have shown that these threshold concentrations were significantly reduced. It is concluded that the facilitation by adrenolytics of gnawing response to apomorphine is caused by an increase in the sensitivity of structures involved in this phenomenon to this dopaminergic stimulant.

Alterations in apomorphine concentration in spinal cord and brain follow the time course of catalepsies induced by different treatments

Because evidence for the neurotransmitter role of dopamine in the gray matter of the spinal cord is accumulating, a question arises of whether or not spinal dopamine receptors are also involved in the effects of dopaminomimetics which are believed to induce beneficial effects in Parkinson's disease through an action thought to be mediated mainly by striatal dopamine receptors. To test this hypothesis muscimol and picrotoxin were injected unilaterally into the posterior part of the substantia nigra of rabbits permanently implanted with stainless-steel cannulae. Muscimol (a GABA-mimetic) enhanced locomotor activity, evoked a stereotyped behavior and contralateral rotations, and increased apomorphine-induced gnawing. Picrotoxin, a substance which inhibits GABA transmission, induced ipsilateral rotations, evoked catalepsy and muscle rigidity, and inhibited locomotor activity. Picrotoxin abolished apomorphine-induced gnawing, and increased haloperidol-mediated catalepsy. The catalepsy induced by an intranigral injection of picrotoxin, and the picrotoxin-evoked blockade of the apomorphine-induced gnawing disappeared within 16 h after the intranigral injection. Alterations in the apomorphine concentration in brain structures (n. caudatus and cerebral cortex) and in spinal cord after picrotoxin injection followed the same time course as the behavioral changes, and returned to the control values 16 h after injection of picrotoxin. Apomorphine was always injected 30 min before the rabbits were killed. Moreover, the substantial increase (to 300%) in apomorphine concentration in the spinal cord probably reflects the antagonism between behavioral changes induced by picrotoxin and the haloperidol catalepsy, rather than the decreased apomorphine concentrations observed in the brain structures. We suggest, therefore, that there exists a correlation between the behavioral effects, which are generally accepted as laboratory models of Parkinson's disease, and the enhanced apomorphine concentration in the spinal cord.

Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat

Specific [3H]-spiperone and [3H]-N,n-propylnorapomorphine (NPA) binding was measured in striatum and substantia nigra of the rat following unilateral 6-hydroxydopamine (6-OHDA) lesions of the medial forebrain bundle, kainic acid lesions of the substantia nigra or striatum, and following decortication. Binding sites labelled by [3H]-spiperone in striatum were found to lie on striatal cell bodies and on the terminals of cortico-striate glutamate fibres, but not on presynaptic dopamine terminals. In contrast, binding sites labelled by [3H]-NPA were demonstrated on striatal cell bodies and on the terminals of nigro-striata dopamine fibres, but not on cortical afferents. In substantia nigra, specific [3H]-spiperone binding sites were found only on non-dopamine cell bodies. No clear evidence was found for their existence on dopamine cell bodies, the terminals of strio-nigral fibres or the terminals of cortico-nigral fibres. In contrast, specific binding sites for [3H]-NPA were found on dopamine cell bodies and the terminals of strio-nigral fibres. Localization on non-dopamine cell bodies or on cortico-nigral fibres was not demonstrated. These studies support the concept of differential localization of agonist and antagonist binding sites.

Analysis of N-n-propylnorapomorphine in plasma and tissue by capillary gas chromatography--electron-capture detection

Capillary gas chromatography combined with electron-capture detection (GC-ECD) was applied to the detection and quantitation of N-n-propylnorapomorphine (NPA) and related compounds in serum and tissue using trifluoroacetyl (TFA) derivatives. The detection limits for NPA using GC-ECD of TFA derivative extend into the subpicogram level, but quantitation in serum was limited to levels of 100 ng/ml due to matrix interferences. The method was applied to the analysis of NPA in rat serum after administration of a moderate dose of the drug and was applied to the detection of NPA in rat brain after the peripheral administration of (-)10,11-methylenedioxy-N-n-propylnoraporphine (MDO-NPA). These results support previous proposals that MDO-NPA is a prodrug of NPA, which acts at cerebral dopamine-receptors.